ArticleFrontiers in pharmacology2025
Stearyl amine-modified elastic cerosomes for boosting the anti-cancer activity of albendazole.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Folate-modified chitosan nanocarriers in precision oncology: molecular engineering, targeted drug delivery, and clinical perspectives.Medical oncology (Northwood, London, England) · 2026Review
- Repurposing Niflumic Acid-Loaded PEGylated Cerosomes for Topical Solid Ehrlich's Carcinoma Management via EGFR/ERK/miR-21 Signaling Pathway Modulation.Pharmaceutics · 2026Article
- Terpene-Enriched Nitazoxanide-Loaded Chondrosomes: Aerodynamic Characterization and In Silico Evaluation of Antiviral Activity.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Terpene-enhanced olaminogel for superior vaginal permeation: robust assessment through in vitro, microbiological, ex vivo, and in vivo evaluations.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ketoprofen-loaded quatsomes as a smart repurposed antifungal therapy for vaginal infections: formulation, characterization, and microbiological evaluation.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Albendazole (ALB), originally developed as an anthelmintic agent, has been repurposed for use in cancer therapy. In the present work, ALB was incorporated into stearyl amine (SA)-based elastic cerosomes (EC) to improve its anticancer activity. Methods: Stearyl amine elastic cerosomes containing albendazole (SA-EC-ALB) were formulated using the thin-film hydration method. A D-optimal experimental design was applied via Design-Expert® software (version 7) generating 19 formulations. The independent variables included SAA amount (X1), sonication time (X2), ceramide type (X3), and SAA type (X4), while the dependent variables were entrapment efficiency (EE%; Y1), particle size (PS; Y2), and polydispersity index (PDI; Y3). Results: The optimized SA-EC-ALB formulation, prepared with ceramide III and Pluronic L121 through sonication, achieved an entrapment efficiency (EE%) of 92.03 ± 3.53% and a particle size (PS) of 312.05 ± 9.32 nm. Conclusion: Loading ALB into SA-EC could potentially induce its anticancer effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.